Abstract
The immune system, which is indispensible for controlling neoplasias, relies on its innate and acquired immunity components to mount an effective response against tumors. In this context, dendritic cells (DCs) are seen as the best antigen-presenting cells because of their capacity for cross-presentation, which can activate both T-helper and cytotoxic lymphocytes. Thus immunotherapy with DCs is considered promising, especially for early-stage cancers. This article provides a clarifying review of recent perspectives on the development of cancer immunotherapy, which has a wide potential for therapeutic applications, and of patents related to immunotherapy with DCs.
Keywords: Cancer, dendritic cells, immunotherapy, immune response, therapeutic potential, tumor.
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Title:Immunotherapy with Dendritic Cells as a Cancer Treatment: Perspectives and Therapeutic Potential
Volume: 7 Issue: 3
Author(s): Andre A.R. Aleixo, Márcia A. Michelin and Eddie F.C. Murta
Affiliation:
Keywords: Cancer, dendritic cells, immunotherapy, immune response, therapeutic potential, tumor.
Abstract: The immune system, which is indispensible for controlling neoplasias, relies on its innate and acquired immunity components to mount an effective response against tumors. In this context, dendritic cells (DCs) are seen as the best antigen-presenting cells because of their capacity for cross-presentation, which can activate both T-helper and cytotoxic lymphocytes. Thus immunotherapy with DCs is considered promising, especially for early-stage cancers. This article provides a clarifying review of recent perspectives on the development of cancer immunotherapy, which has a wide potential for therapeutic applications, and of patents related to immunotherapy with DCs.
Export Options
About this article
Cite this article as:
Aleixo A.R. Andre, Michelin A. Márcia and Murta F.C. Eddie, Immunotherapy with Dendritic Cells as a Cancer Treatment: Perspectives and Therapeutic Potential, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2013; 7 (3) . https://dx.doi.org/10.2174/18722148113079990001
DOI https://dx.doi.org/10.2174/18722148113079990001 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
Urease and α-Chymotrypsin Inhibitory Effects of Selected Urea Derivatives
Letters in Drug Design & Discovery Biofunctional Peptides from Milk Proteins: Mineral Binding and Cytomodulatory Effects
Current Pharmaceutical Design Advances in Nanocarriers for Anticancer Drugs Delivery
Current Medicinal Chemistry <i>Anastatica hierochuntica </i>Extracts: Promising, Safe and Selective Anticancer Agents
The Natural Products Journal PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs
Current Pharmaceutical Design Encouraging microRNA-based Therapeutic Strategies for Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Antimitotic Chalcones and Related Compounds as Inhibitors of Tubulin Assembly
Anti-Cancer Agents in Medicinal Chemistry Dual Induction of Mitochondrial Apoptosis and Senescence in Chronic Myelogenous Leukemia by Myrtucommulone A
Anti-Cancer Agents in Medicinal Chemistry Low Molecular Weight and Oligomeric Chitosans and Their Bioactivities
Current Topics in Medicinal Chemistry Targeting the p53 Pathway of Apoptosis
Current Pharmaceutical Design Malignant Mesothelioma: Biology, Diagnosis and Therapeutic Approaches
Current Molecular Pharmacology Pgp and FLT3: Identification and Modulation of Two Proteins that Lead to Chemotherapy Resistance in Acute Myeloid Leukemia
Current Medicinal Chemistry Somatostatin and Octreotide on the Treatment of Acute Pancreatitis - Basic and Clinical Studies for Three Decades
Current Pharmaceutical Design The Efficacy of Vitamin K, A Member Of Naphthoquinones in the Treatment of Cancer: A Systematic Review and Meta-Analysis
Current Cancer Drug Targets CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies
Current Cancer Drug Targets Prevention and Treatment of Bone Metastases
Current Pharmaceutical Design Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a Trend in Both Cancer Gene Therapy and Cancer Virotherapy
Current Pharmaceutical Biotechnology Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection
Current Molecular Pharmacology Aldehyde Dehydrogenase as a Marker for Stem Cells
Current Stem Cell Research & Therapy Cancer Stem Cell Markers in Nasopharyngeal Carcinoma and Its Relevance for Therapy
Current Traditional Medicine